Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -44.11% is in line with its 5-year average of -40.75%, near the high end of its 5-year range (-193.37%–5.70%).
23.93% below its 12-month average of -35.59%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2025-12-31): -19.02%.
EBITDA MARGIN
-44.11%
EBITDA MARGIN AVG TTM
-35.59%
EBITDA MARGIN AVG 3Y
-56.44%
EBITDA MARGIN AVG 5Y
-40.75%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-23.93%
CURRENT VS 3Y AVG
+21.85%
CURRENT VS 5Y AVG
-8.23%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Mobile-health Network Solutions Class A Ordinary Shares
Market Cap
$30263.00
EBITDA Margin
-44.11%
TTM Avg
-35.59%
3Y Avg
-56.44%
5Y Avg
-40.75%
Market Cap
$30924.00
EBITDA Margin
-51.60%
TTM Avg
-25.53%
3Y Avg
-32.59%
5Y Avg
-16.80%
Market Cap
$5976.00
EBITDA Margin
-216.38%
TTM Avg
-116.97%
3Y Avg
-54.20%
5Y Avg
-40.74%
Market Cap
$63276.00
EBITDA Margin
-1762.94%
TTM Avg
-1134.94%
3Y Avg
-792.43%
5Y Avg
-12891.91%
Market Cap
$70876.00
EBITDA Margin
-24782.35%
TTM Avg
-24782.35%
3Y Avg
-17538.85%
5Y Avg
-17538.85%
Market Cap
$109735.00
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$245237.00
EBITDA Margin
-994.74%
TTM Avg
-759.01%
3Y Avg
-558.46%
5Y Avg
-556.54%
Market Cap
$380715.00
EBITDA Margin
-47981.26%
TTM Avg
-69951.07%
3Y Avg
-52738.28%
5Y Avg
-42190.63%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR) | $30263.00 | -44.11% | -35.59% | -56.44% | -40.75% |
| Zhongchao Inc. (ZCMD)vs › | $30924.00 | -51.60% | -25.53% | -32.59% | -16.80% |
| NewGenIvf Group Limited (NIVF)vs › | $5976.00 | -216.38% | -116.97% | -54.20% | -40.74% |
| Akanda Corp. (AKAN)vs › | $63276.00 | -1762.94% | -1134.94% | -792.43% | -12891.91% |
| PRF Technologies Ltd. (PRFX)vs › | $70876.00 | -24782.35% | -24782.35% | -17538.85% | -17538.85% |
| Psyence Biomedical Ltd. (PBM)vs › | $95097.00 | N/A | N/A | N/A | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $109735.00 | N/A | N/A | N/A | N/A |
| SciSparc Ltd. (SPRC)vs › | $245237.00 | -994.74% | -759.01% | -558.46% | -556.54% |
| Virax Biolabs Group Limited (VRAX)vs › | $380715.00 | -47981.26% | -69951.07% | -52738.28% | -42190.63% |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | -2196.68% | -1727.24% | -1664.72% | -2055.32% |
Gross Margin
-11.4%
EBITDA Margin
-44.1%
Operating Margin
-46.4%
Net Margin
-44.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | -19.02% |
| 2025-06-30 | -50.15% |
| 2024-12-31 | -37.61% |
| 2024-06-30 | -193.37% |
| 2023-12-31 | -15.51% |
| 2023-06-30 | -38.22% |
| 2022-12-31 | -41.21% |
| 2022-06-30 | 4.98% |
| 2021-12-30 | 5.70% |
| 2021-06-30 | -23.14% |
| 2020-12-30 | -23.14% |
